Literature DB >> 30316681

Circulating microRNA plasma profile in MuSK+ myasthenia gravis.

Liis Sabre1, Jeffrey T Guptill2, Melissa Russo2, Vern C Juel2, Janice M Massey2, James F Howard3, Lisa D Hobson-Webb2, Anna Rostedt Punga4.   

Abstract

Muscle-specific tyrosine kinase antibody positive myasthenia gravis (MuSK+ MG) is an immunological subtype with distinctive pathogenic mechanisms and clinical features. The aim of this study was to analyze the circulating plasma microRNA profile of patients with MuSK+ MG. From the discovery cohort miR-210-3p, miR-324-3p and miR-328-3p were further analyzed in the validation cohort. We found a distinct plasma profile of miR-210-3p and miR-324-3p that were significantly decreased in MuSK+ MG patients compared to healthy controls (4.1 ± 1.4 vs 5.1 ± 1.4, p = .006 and 4.7 ± 1.0 vs 5.4 ± 1.3, p = .02). These findings reveal a distinct plasma miRNA profile in MuSK+ MG.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biomarker; MuSK; Muscle-specific tyrosine kinase; Myasthenia gravis; microRNA

Mesh：

Substances：

Year:  2018        PMID： 30316681      PMCID： PMC6240475          DOI： 10.1016/j.jneuroim.2018.10.003

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN： 0165-5728            Impact factor:   3.478


  32 in total

1.  Analysis of circulating microRNA: preanalytical and analytical challenges.

Authors:  Jennifer S McDonald; Dragana Milosevic; Honey V Reddi; Stefan K Grebe; Alicia Algeciras-Schimnich
Journal:  Clin Chem       Date:  2011-04-12       Impact factor: 8.327

Review 2.  MiRNA-210: A Current Overview.

Authors:  Alberto Bavelloni; Giulia Ramazzotti; Alessandro Poli; Manuela Piazzi; Enrico Focaccia; William Blalock; Irene Faenza
Journal:  Anticancer Res       Date:  2017-12       Impact factor: 2.480

3.  T cell repertoire in DQ5-positive MuSK-positive myasthenia gravis patients.

Authors:  Mariapaola Marino; Maria Teresa Maiuri; Gabriele Di Sante; Flavia Scuderi; Francesca La Carpia; Nikolaos Trakas; Carlo Provenzano; Paraskevi Zisimopoulou; Francesco Ria; Socrates J Tzartos; Amelia Evoli; Emanuela Bartoccioni
Journal:  J Autoimmun       Date:  2014-01-04       Impact factor: 7.094

Review 4.  Muscle autoantibodies in myasthenia gravis: beyond diagnosis?

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Expert Rev Clin Immunol       Date:  2012-07       Impact factor: 4.473

5.  Racial differences in myasthenia gravis in Alabama.

Authors:  Shin J Oh; Marla B Morgan; Liang Lu; Yuki Hatanaka; Shoji Hemmi; Angela Young; Gwendolyn C Claussen
Journal:  Muscle Nerve       Date:  2009-03       Impact factor: 3.217

6.  Analysis of serum miRNA profiles of myasthenia gravis patients.

Authors:  Gisela Nogales-Gadea; Alba Ramos-Fransi; Xavier Suárez-Calvet; Miquel Navas; Ricard Rojas-García; Jose Luis Mosquera; Jordi Díaz-Manera; Luis Querol; Eduard Gallardo; Isabel Illa
Journal:  PLoS One       Date:  2014-03-17       Impact factor: 3.240

7.  Identification of circulating microRNAs for the differential diagnosis of Parkinson's disease and Multiple System Atrophy.

Authors:  Annamaria Vallelunga; Marco Ragusa; Stefania Di Mauro; Tommaso Iannitti; Manuela Pilleri; Roberta Biundo; Luca Weis; Cinzia Di Pietro; Angela De Iuliis; Alessandra Nicoletti; Mario Zappia; Michele Purrello; Angelo Antonini
Journal:  Front Cell Neurosci       Date:  2014-06-10       Impact factor: 5.505

8.  Circulating miRNAs in myasthenia gravis: miR-150-5p as a new potential biomarker.

Authors:  Tanel Punga; Rozen Le Panse; Mats Andersson; Frédérique Truffault; Sonia Berrih-Aknin; Anna R Punga
Journal:  Ann Clin Transl Neurol       Date:  2013-12-30       Impact factor: 4.511

9.  Identification of suitable reference gene and biomarkers of serum miRNAs for osteoporosis.

Authors:  Jian Chen; Kai Li; Qianqian Pang; Chao Yang; Hongyu Zhang; Feng Wu; Hongqing Cao; Hongju Liu; Yumin Wan; Weibo Xia; Jinfu Wang; Zhongquan Dai; Yinghui Li
Journal:  Sci Rep       Date:  2016-11-08       Impact factor: 4.379

10.  Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status.

Authors:  Shin Joong Oh
Journal:  J Clin Neurol       Date:  2009-06-30       Impact factor: 3.077
View more
  3 in total

Review 1.  A Review on the Role of Non-Coding RNAs in the Pathogenesis of Myasthenia Gravis.

Authors:  Soudeh Ghafouri-Fard; Tahereh Azimi; Bashdar Mahmud Hussen; Mohammad Taheri; Reza Jalili Khoshnoud
Journal:  Int J Mol Sci       Date:  2021-11-30       Impact factor: 5.923

2.  Myasthenia gravis with anti-muscle-specific tyrosine kinase antibodies during therapy for multiple myeloma: a case report.

Authors:  Shoko Sakano; Hirofumi Matsuyama; Hidehiro Ishikawa; Akihiro Shindo; Yuichiro Ii; Keita Matsuura; Minoru Mizutani; Norikazu Kawada; Hidekazu Tomimoto
Journal:  BMC Neurol       Date:  2020-06-12       Impact factor: 2.474

Review 3.  Circulating miRNAs as Potential Biomarkers in Myasthenia Gravis: Tools for Personalized Medicine.

Authors:  Liis Sabre; Tanel Punga; Anna Rostedt Punga
Journal:  Front Immunol       Date:  2020-03-04       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.